← All trials
NCT01087242
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2009
- Primary completion
- Dec 1, 2009
- Completion date
- Jun 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 480
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- Tianjin University of Traditional Chinese MedicineCollaborator
- Shanghai University of Traditional Chinese MedicineCollaborator
- China Academy of Chinese Medical SciencesStudy chair
- Peking UniversityCollaborator
- Tasly Pharmaceuticals, Inc.Collaborator
- Liaoning Hospital of Traditional Chinese MedicineCollaborator
- Tianjin UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.